Peer-reviewedCC BY-NC-NDTranslational cancer research
Rational triplet therapy after CDK4/6 inhibition: what TAKTIC adds and what it cannot resolve.
- 1Division of Clinical Research and Technological Development, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil.
- 2Instituto Estadual de Oncologia da Baixada, Rio de Janeiro, Brazil.
Related
- AGE-related efficacy and safety of darolutamide triplet therapy in metastatic hormone-sensitive prostate cancer: are we ready for routine clinical practice?
- Patient-tailored azacitidine, venetoclax and gilteritinib triplet therapy appear to improve tolerability while preserving encouraging clinical outcomes in FLT3-mutated relapsed/refractory AML.
- From MEK inhibition to rational combination strategies for NF1-associated plexiform neurofibromas
- A retrospective comparative study of a full-course precision MDT nursing studio model integrating rational emotive behavior therapy for standardized health management during pregnancy
- Dual-pathway targeted therapy for decompensated cirrhosis: Combined transjugular intrahepatic portosystemic shunt and cyclooxygenase-2 inhibition
BibTeX
@article{silva2026rational,
title = {{Rational triplet therapy after CDK4/6 inhibition: what TAKTIC adds and what it cannot resolve.}},
author = {Jessé Lopes da Silva and Thales de Sousa Ferreira da Silva and Andréia Cristina de Melo},
journal = {Translational cancer research},
year = {2026},
month = oct,
doi = {10.21037/tcr-2026-2500},
url = {https://europepmc.org/article/MED/42997726},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Rational triplet therapy after CDK4/6 inhibition: what TAKTIC adds and what it cannot resolve.
AU - Jessé Lopes da Silva
AU - Thales de Sousa Ferreira da Silva
AU - Andréia Cristina de Melo
PY - 2026
DA - 2026/10/19
JO - Translational cancer research
DO - 10.21037/tcr-2026-2500
UR - https://europepmc.org/article/MED/42997726
SN - 2218-676X
SN - 2219-6803
ER -